Abstract. Intracerebral administration of ibotenate produces, through activation of N-methyl-D-aspartate (NMDA) receptors, neuronal heterotopias in the newborn hamster neocortex: high doses of ibotenate induce periventricular and subcortical neuronal heterotopias, while low doses of ibotenate produce intracortical heterotopias and molecular layer ectopias. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are closely related peptides with neurotrophic properties. They share common VPAC 1 and VPAC 2 receptors, which use cAMP as a second messenger. Previous studies have shown that VIP prevents excitotoxic neuronal death and exacerbates glutamate-induced c-fos neuronal expression. In order to gain new insight into the molecular control of neuronal migration, the present study examined the effects of VIP and PACAP on ibotenate-induced heterotopias in the newborn hamster. Co-treatment with VIP and a high dose of ibotenate produced a pattern of neuronal heterotopias similar to the one observed in animals treated with low doses of ibotenate alone. Pups co-injected with a low dose of ibotenate and a VIP antagonist displayed cortical dysgeneses similar to those observed in animals treated with high doses of ibotenate alone. The modulating effects of VIP on excitotoxin-induced heterotopias were mimicked by forskolin, PACAP, and by a specific VPAC 2 receptor agonist but not by a VPAC 1 agonist, and were blocked by a protein kinase A (PKA) inhibitor. Taken together, these data suggest that VIP and PACAP can attenuate ibotenateinduced heterotopias in newborn hamster and that this effect is mediated by the VPAC 2 receptor utilizing the cAMP-PKA pathway.
INTRODUCTION
Neuroblast migration from the periventricular germinative zone towards the emerging cortical plate is a critical step in neocorticogenesis. Among the factors controlling neuronal migration described thus far (for reviews, see references 1, 2), the neurotransmitters GABA and glutamate play a major role. Komuro and Rakic (3) first reported that blockade of the N-methyl-Daspartate (NMDA) glutamate receptor subtype slowed down the migration rate of cultured cerebellar neurons, and Behar et al (4, 5) showed chemotactic effects of both GABA and NMDA agonists on cultured cortical neurons. Further confirmation of the role of glutamate came from additional experiments (6) in which focal injections of different concentrations of the NMDA receptor agonist ibotenate into the neopallium of hamsters on the day of birth, a stage where neurons destined to the superficial cortical layers are migrating, produced different patterns of neuronal heterotopias. In that study, lower doses of ibotenate induced intracortical heterotopias and molecular layer ectopias while higher doses produced either a laminar band heterotopia or focal periventricular nodular heterotopias. Immunohistochemical analysis revealed that most of heterotopic cells were labeled with antibodies recognizing microtubule-associated proteins, supporting their neuronal nature (6) . Thus, ibotenate, a unique molecular trigger of the excitotoxic cascade, produced a dose-dependent spectrum of neuronal heterotopias mimicking neuronal migration disorders encountered in humans (6) .
Binding sites for vasoactive intestinal peptide (VIP) have been described in the rat intermediate zone at a time corresponding to the migration of the supragranular neurons (7) , suggesting the potential involvement of VIP in modulating neuronal migration. VIP shares a high sequence homology with pituitary adenylate cyclase-activating polypeptide (PACAP), which exists in 2 biologically active forms of 27 (PACAP 27) and 38 (PACAP 38) amino acids. VIP and PACAP display similar affinities for 2 receptors which have been called VPAC 1 (type I common receptor for VIP and PACAP), VIP (8, 9) , and VPAC 2 (type II common receptor for VIP and PACAP) (10, 11) ; these VPAC receptors are coupled to adenylyl cyclase activation (12, 13) . In addition, PACAP, but not VIP, also acts on PAC 1 (type I specific receptor for PA-CAP) receptors (14) .
VIP is a central nervous system neurotransmitter and neuromodulator with neurotrophic properties including enhanced survival of cultured neurons (15, 16) , promotion of early embryonic growth (17) , modulation of astrocytogenesis (18, 19) , and neuroprotection against HIVinduced cell death (20) . Several roles of PACAP have also been described during brain development including in vitro neuronal survival (21) and inhibition of neuronal progenitor proliferation (22) . VIP and PACAP can interact with glutamatergic pathways as demonstrated by their ability to exacerbate glutamate-induced c-fos expression in cultured neurons (23) , and VIP attenuation of excitotoxin-induced pulmonary edema (24) and neonatal brain lesions (25, 26) .
These data prompted us to investigate the modulating effects of VIP and PACAP on ibotenate-induced heterotopias in newborn hamster brain. Receptors and transduction pathways involved were evaluated by the use of specific agonists and antagonists.
MATERIAL AND METHODS

Drug Administration
Golden hamsters were chosen for this study because migration of neurons destined to the superficial neocortical layers is still largely ongoing at birth. Pregnant golden hamsters were housed in groups and fed with laboratory chow and water ad libitum. All experimental protocols and procedures complied with guidelines of the INSERM. For experiments, several litters of pups of both sexes were used. As previously described in rodents (6, (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) , at postnatal day (P) 0, pups were anesthetized with ether and kept under a warming lamp. Intracerebral injections were performed with a 26-gauge needle on a 50 l Hamilton syringe mounted on a calibrated microdispenser. The needle was inserted 2 mm under the external surface of scalp skin in the frontoparietal area of the right hemisphere 2 mm from the midline (in the lateral-medial plane) and 3 mm from the junction between the sagittal and lambdoid sutures (in the rostro-caudal plane). In all these experiments, the tip of the needle reached the periventricular intermediate zone (additional animals injected with toluidine blue confirmed the correct positioning of the needle). Two 1-l boluses were injected 30 s apart. The needle was left in place for 30 s after the second bolus. After the injections, pups were allowed to recover from anesthesia and were returned to their dams.
Brain Analysis
Five days after injections, the surviving pups were killed by decapitation. Brains were removed and fixed in 4% formalin for 7 days prior to paraffin embedding. Coronal serial sections, 15-m-thick, were cut and every third section was stained with cresyl-violet. Brains were completely and serially sectioned from the frontal pole to the occipital lobes permitting accurate detection and characterization of cortical dysgeneses. Neuronal heterotopias were defined by their location (ectopias in the molecular layer, intracortical heterotopias or focal periventricular or subcortical nodular heterotopias). The occurrence of each type of heterotopia was scored 1 versus 0 for no occurrence. Therefore, the mean value of each type of heterotopia in each group was between 0 and 1 (multiplied by 100 when expressed as percentage) and reflected the proportion of hamsters that showed this type of cortical dysgenesis. This variable was analyzed using analysis of variance (ANOVA) with Dunnet's multiple comparison of means test (36) .
Serial sectioning of the brains also permitted detection of any destructive cortical lesions and the measurement of their sagittal fronto-occipital diameter. The maximal sagittal fronto-occipital diameter was defined as the number of coronal sections where the lesion was present multiplied by 15 m and was used as an index of the volume of the lesion. In the present paper, this maximal diameter will be referred as the length of the lesion in the sagittal fronto-occipital axis. Results were expressed as means Ϯ standard error of mean (SEM) and statistical analyses were performed by ANOVA with Dunnet's multiple comparison of means test or by Student t-test. Brain sections were examined and scored by 2 separate investigators unaware of the experimental groups.
Drugs and Experimental Groups
Ibotenate (Sigma, Saint Louis, MO), VIP (Peninsula Laboratories, St. Helens, UK), PACAP 38 (Peninsula Laboratories), and neurotensin 1-6 VIP 7-28 hybrid (Bachem, Voisins-les-Bretonneux, France) were diluted in 0.02% acetic acid-0.1 M phosphate buffer saline (PBS). RO 25-1553 and [Arg 16 ] chicken secretin were synthesized as previously described (37, 38) and diluted in 0.1M PBS. Forskolin (Biomol, Plymouth Meeting, CA) was diluted in 0.01% acetic acid-0.05% dimethyl-sulfoxide-0.1 M PBS. H89 (Biomol), a protein kinase A (PKA) inhibitor, was diluted in 0.01% acetic acid-1% methanol-0.05% dimethyl-sulfoxide-0.1 M PBS.
Ibotenate, a glutamate analog, activates both NMDA and metabotropic receptors but not alpha-3-amino-hydroxy-5-methyl-4-isoxazole (AMPA) and kainate receptors. Previous studies showed that ibotenate effects on the newborn hamster, mouse and rat brain were mediated through NMDA receptors (6, 29, 34) . The neurotensin-VIP hybrid is a peptide consisting of a carboxy fragment of VIP (VIP 7-28) and a 6-amino acid fragment of neurotensin, and is a specific VIP antagonist (VA) with no agonist activity (13, 39, 40) . Co-treatment with neurotensin did not influence the biological activity associated with VA (41) . The affinity of VA for VPAC 1 , VAPC 2 , and PAC 1 receptors has not been published. RO 25-1553 is a long-acting cyclic VIP analogue (42) selective for the VPAC 2 receptor subclass (37) . [Arg 16 ] chicken secretin is selective for the VPAC 1 receptor subclass (38) . Forskolin is an adenylate cyclase activator and H89 is a cAMP-dependent protein kinase or PKA inhibitor.
In the first set of experiments, 10 g ibotenate was intracerebrally co-injected with 1 of the following peptides or combination of peptides: 1 g (n ϭ 11), 0.1 g (n ϭ 15), or 0.01 g (n ϭ 8) VIP; 1 g VIP ϩ 1 g VA (n ϭ 7); 1 g PACAP 38 (n ϭ 6); 10 g RO 25-1553 (n ϭ 10); 10 g [Arg 16 ] chicken secretin (n ϭ 8); 1 g VIP ϩ 5 g H89 (n ϭ 8); 5 g forskolin (n ϭ 6); controls were treated with ibotenate (n ϭ 43). In another group of experiments, pups were intracerebrally co-treated with 0.1 g ibotenate alone (controls; n ϭ 12) or with 0.1 g ibotenate and 1g VA (n ϭ 7). Other animals received only PBS (n ϭ 6) or 1 g VIP (n ϭ 5) without any ibotenate. In the last experimental set, intraperitoneal injection of 10 g RO 25-1553 (n ϭ 5) or 5 g VA (n ϭ 5) was performed without intracerebral injection. Mortality varied randomly within experimental groups due to the unpredictable behavior of some mothers following pup manipulation; therefore, numbers (n) given above do not reflect the numbers of injected pups but the numbers of analyzed brains. Doses of intracerebrally injected drugs were selected on the basis of previous studies using a similar animal model of neonatal excitotoxic brain lesions in mice (6, (25) (26) (27) . Previous studies have shown that 10 g RO 25-1553 given by intraperitoneal route significantly protected the mouse newborn white matter against an excitotoxic challenge (27) and that 5 g VA administered intraperitoneally inhibited neocortical astrocytogenesis in newborn mice (42) . Pups from at least 2 different litters were used in each experimental group and values were obtained from 2 or more successive experiments.
Study of Cell Death (Fragmented DNA)
To further quantify the degree of neuronal loss produced by ibotenate treatment, cell death was detected using an in situ cell death detection kit as directed (Roche, Meylan, France). Pups co-treated as described above with ibotenate and 1 g VIP (n ϭ 5), 1 g PACAP (n ϭ 5), or PBS (n ϭ 5) were killed 24 h later. Following formalin fixation and paraffin embedding, coronal sections, 15-m-thick, were deparaffinized, treated for 20 min at 37ЊC with 20mg/ml proteinase K and incubated for 2 min on ice with 0.1% triton X-100. DNA strands breaks were identified by labeling for 60 min at 37ЊC free 3Ј-OH termini with terminal deoxynucleotidyl transferase (Tdt) using nucleotides labeled with fluorescein. Incorporated nucleotides were detected with an anti-fluorescein antibody conjugated with alkaline phosphatase, using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate toluidonium salt as substrate. ''Tunel-'' (Tdt-mediated dUTP nick end labelling) positive cells were counted in a 0.01 mm 2 area of the cortical plate at the site of ibotenate injection. Sixteen nonadjacent fields from 5 brains were studied in each group. Results were expressed as means ϩ SEM and statistical analyses were performed by ANOVA with Dunnet's multiple comparison of means test.
VIP Binding Sites Analysis
The fresh, frozen brains of 5 P0 golden hamsters were cut in the coronal plane at 20 m on a cryostat. Sections were placed under vacuum at 4ЊC for at least 20 h before being stored at Ϫ70ЊC until use. As described previously, the slides were thawed at room temperature and preincubated for 30 min in 10 mM HEPES, 130 mM NaCl, 4.7 mM KCl, 5 mM MgCl 2 , 5 mM MnCl 2 1 mM ethylenediaminetetraacetate, 1% bovine serum albumin, with pH adjusted to 7.4 with NaOH. Following preincubation, the slides were incubated for 1 h at room temperature in the same buffer containing 1 mg/ml bacitracin and 50 pM 125 I-labeled VIP (Amersham), with or without 10 Ϫ6 M unlabeled VIP (Peninsula) to determine specific binding. The slides were then washed in three 1-min rinses of cold PBS, pH 7.4, and rapidly dried with forced air. Sections were exposed to Amersham Hyperfilm- 
RESULTS
Neuronal Heterotopias
Intracerebral injection of ibotenate induced 3 types of neuronal heterotopias: 1) spherical nodular heterotopias in the periventricular and intermediate zones (Fig. 1A); 2) intracortical heterotopias (Fig. 1B) ; and 3) ectopias in the molecular layer (Fig. 1C) . Molecular layer ectopias were observed isolated or in combination with the other types of heterotopias. Neuronal heterotopias were detected in all pups injected with ibotenate. The pattern of neuronal heterotopias was dependent upon the dose of ibotenate administered: pups treated with 10 g ibotenate displayed mostly periventricular or intermediate zone heterotopias, while animals injected with 0.1 g ibotenate had molecular layer ectopias and intracortical heterotopias (Figs. 1, 2) . Confirming the specificity of ibotenate treatment, injection of PBS alone did not result in any detectable heterotopia and produced only a needle tract (data not shown).
Although all pups co-treated intracerebrally with ibotenate and another drug (or combination of drugs) displayed focal heterotopias, the pattern of brain dysgenesis was attenuated when compared with animals injected with ibotenate alone. Co-treatment with 10 g ibotenate and VIP induced a dose-dependent attenuation of the dysgenetic pattern (Figs. 2, 3 ) with a decreased proportion of periventricular/intermediate zone heterotopias and an increased proportion of intracortical heterotopias and molecular layer ectopias. The resulting distribution of heterotopias obtained in pups co-treated with 10 g ibotenate and 1 g VIP was very close to the pattern observed in pups treated with 0.1 g ibotenate alone. In contrast, animals co-treated with 0.1 g ibotenate and VA displayed mostly periventricular/intermediate zone heterotopias with very few intracortical heterotopias or molecular layer ectopias (Figs. 2, 3) , mimicking the brain dysgeneses observed in pups treated with 10 g ibotenate alone. Co-treatment with 10 g ibotenate, 1 g VIP, and 1 g VA abolished the VIP-induced modulation of neuronal heterotopias (Fig. 2) . Co-treatment with PACAP 38, RO 25-1553 or forskolin, but not with [Arg 16 ] chicken secretin, reproduced the VIP effects on ibotenate-induced heterotopias (Fig. 4) . Co-injection of [Arg 16 ] chicken secretin slightly increased the proportion of ibotenate-induced intracortical heterotopia without reaching statistical significance (Fig. 4B) . Addition of H89 blocked VIP-induced modulation of excitotoxic heterotopias (Fig. 4) .
Intracerebral injection of VIP alone, in the absence of any excitotoxic insult, did not induce any detectable heterotopia (data not shown). Intraperitoneal injection of RO 25-1553 or VA had no detectable effect on brain morphology or cytoarchitecture (data not shown).
Destructive Lesions
As previously described (6), ibotenate also produced a dose-dependent focal death of post-migratory neurons in layers V-VIa (Figs. 5A, 6A ). This cortical lesion was associated with the formation of a sulcus (Fig. 5A ) and was located in the rostral part of the injection site. (Figs. 5, 6 ). VIP-induced neuroprotection was dose-dependent and was blocked by co-treatment with VA but not with H89 (Fig. 6) . VA significantly increased neuronal death induced by the injection of 0.1 g ibotenate (Fig. 6A) .
Animals treated intracerebrally with VIP or PBS alone did not display any detectable neuronal death beyond the needle tract (data not shown). Intraperitoneal injection of VA or RO 25-1553 did not produce any detectable brain lesions (data not shown).
Tunel staining 24 h following ibotenate confirmed data obtained from cresyl-violet stained sections: 1) in pups injected with ibotenate alone, numerous stained nuclei were detected at the site of injection, especially in the deep cortical layers (Fig. 7A, C) ; 2) co-treatment with VIP significantly reduced the severity of ibotenate-induced cell death (Fig. 7B, C) ; and 3) in contrast, PACAP had no detectable effect on the excitotoxic cell death (Fig.  7C) .
Distribution of VIP Binding Sites
VIP binding sites were widely distributed throughout the P0 hamster brain with the highest densities occurring in the suprachiasmatic nucleus and the midline structures of the brainstem. High binding levels were also seen in the circumventricular germinal neuroepithelium throughout the brain (Fig. 8A) , ventral forebrain (VF), pyriform cortex (PC), septum (S), thalamus, colliculi, and brainstem. Within the neocortex, VIP binding was dense in layer 1 (I) and the germinal neuroepithelium surrounding the lateral ventricles (GN), but moderate within the intermediate layers of the neocortex (INT) (Fig. 8A) . VIP binding was specific since unlabeled VIP reduced binding to undetectable levels (Fig. 8B) .
DISCUSSION
The present study showed that both VIP and PACAP can modulate the ibotenate-induced neuronal heterotopias in newborn hamsters. This modulating effect was reproduced by RO 25-1553 and was altered by PKA blockade. VIP effects were inhibited by co-treatment with VA, confirming the specificity of the observed effects. VIP on its own had no detectable influence on neocortical cytoarchitecture in the present model.
An important question is whether VIP and PACAP alter the initial injury caused by ibotenate or whether they 4 . Effects of PACAP 38, specific agonists of VPAC receptors and factors interfering with the cAMP-protein kinase A transduction pathway on the patterns of neuronal heterotopias. All pups were injected with 10 g ibotenate and the drug indicated on the X axis (dose indicated in g). Results are increase the ability of the developing brain to recover from that injury. Although the current study does not directly address this question, previous studies suggest that VIP can promote axonal repair following excitotoxic injury in the newborn mouse pup (26) . Further studies will be necessary to determine if VIP and PACAP can resume a migratory behavior in neurons arrested at a heterotopic location following an excitotoxic challenge.
As previously mentioned, PACAP and VIP share some common receptors called VPAC 1 (8, 9) and VPAC 2 receptors (10, 11) . PACAP, but not VIP, also acts on some PAC 1 receptors (14) . Two transduction pathways have been reported for VIP and PACAP: 1) VIP and PACAP can stimulate the production of cAMP (12, 13); and 2) subnanomolar concentrations of VIP and PACAP stimulate the accumulation of intracellular calcium, increase inositol phosphates in astrocyte cultures (21, 44) , and VIP produces translocation of protein kinase C isozymes (45) . In the present study, the modulation of ibotenate-induced neuronal heterotopias seemed to be mediated by a common VPAC receptor since both VIP and PACAP were effective. The selective VPAC 2 agonist RO 25-1533 (37), but not the selective VPAC 1 agonist [Arg 16 ] chicken secretin (38) , reproduced VIP-PACAP effects on neuronal heterotopias, suggesting the involvement of the VPAC 2 receptor subtype. The use of forskolin and H89 confirmed the involvement of a cAMP-PKA pathway in these VIP-PACAP effects.
Autoradiographic studies confirmed the presence of VIP binding sites in the P0 hamster neopallium. The distribution of the binding sites was compatible with an effect of VIP-PACAP on neuronal precursors in the periventricular germinative zone, migrating neurons, subplate neurons, Cajal-Retzius neurons, or radial glial cells. These different cell populations have indeed been shown to be involved in the control of neuronal migration: 1) according to the seminal discovery of Rakic (46), numerous migrating neurons find their way to the cortical plate by climbing the ascending process of radial glial cells (for reviews, see ref [47] [48] [49] ; 2) events occurring during the mitotic cycle in the germinative zone critically determine the laminar fate of neurons (50-53); 3) previous studies have also suggested that Cajal-Retzius (54, 55) , and subplate neurons (56, 57) are involved in the control of neocortical lamination. Since VPAC receptors have not yet been cloned in the hamster, we were unable to study the precise distribution of the VPAC 2 receptor subtype in this species. Co-treatment with a low dose of ibotenate and VA exacerbated the excitotoxic cortical dysgenesis, suggesting that an endogenous ligand active at the VAPC 2 receptor plays a protective regulatory role against excess NMDA receptor activation. Since VA does not distinguish between the 2 VIP receptor subclasses that recognize VIP and PACAP equally well, the data did not permit the determination of the endogenous peptide responsible for this neuroprotection. Although data on VIP and PACAP production are not available in hamsters, previous studies have addressed this question in mice and rats where neocortical development at embryonic days 17 or 18, respectively, roughly corresponds to the P0 stage in hamsters. With in situ hybridization histology, VIP mRNA was not apparent prenatally in rat brain, and was first easily detectable during the first postnatal week (7); however, Waschek et al (58) have recently described mouse hindbrain cells expressing VIP mRNA as early as E11. PACAP begins to be detectable by RIA in rat neocortex at E18 and its concentration increases during the first 2 postnatal weeks (59) . In situ hybridization detects PA-CAP mRNA in rat upper neocortical layers from E18 on without a significant signal detected in the neocortical germinative zone (Gressens P. and Hill J.M., unpublished observation). Future studies will have to determine the importance of these early born cells that produce VIP and/or PACAP.
Intracerebral injection of VIP and intraperitoneal injections of RO 25-1553 or VA in the absence of any excitotoxic stress did not produce any detectable alteration of cortical cytoarchitecture, confirming previous data obtained with VA administration during neuronal migration in mice (60) . These results suggest that VIP-PACAP serve as protective molecules in pathological situations such as an excitotoxic stress. Experimental evidence suggests that neuronal migration is tightly controlled by NMDA receptor activation: inhibition of NMDA receptors slows down the rate of neuronal migration in vitro (3, 5) while excess of NMDA receptor activation leads to neuronal ectopias and heterotopias in vivo (6, present study). Endogenous VIP-PACAP could represent one of the mechanisms used by the developing neopallium to limit the deleterious effects of excess glutamatergic stimulation. Mechanisms contributing to the maintenance of normal glutamatergic signals during neuronal migration remain to be determined.
Confirming our previous studies (6, 29) , ibotenate also produced cell death of early postmigratory neurons in the deep cortical layers V-VIa. This laminar depopulation associated with formation of an overlying sulcus in the lissencephalic rodent brain mimics the human disorder (poly)microgyria, generally occurring between 20 and 28 wk of gestation. In the present study, VIP, but not PA-CAP, significantly reduced the severity of ibotenate-induced neuronal cell death, confirming data obtained in newborn mice (25, 26) . Taken together, the published and present data suggest that interactions between VIPergic and glutamatergic pathways rely on different receptors and transduction mechanisms depending upon the specific ontogenic events considered.
In conclusion, the present study confirmed that an excess of NMDA receptor activation produces neuronal heterotopias and demonstrated that VPAC receptors and their ligand(s) can attenuate ibotenate-induced cortical dysgeneses.
